FLT3LG and neoplasm: Based on the importance of cross-priming DC in the activation of anti-tumor T cells, a recently opened trial will test the combination of Flt3 ligand, a growth factor for DC, anti-CD40 and chemotherapy in patients with metastatic TNBC68.